Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Soyeon An 1 Article
Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study
Haeryoung Kim, Soyeon An, Kyoungbun Lee, Sangjeong Ahn, Do Youn Park, Jo-Heon Kim, Dong-Wook Kang, Min-Ju Kim, Mee Soo Chang, Eun Sun Jung, Joon Mee Kim, Yoon Jung Choi, So-Young Jin, Hee Kyung Chang, Mee-Yon Cho, Yun Kyung Kang, Myunghee Kang, Soomin Ahn, Youn Wha Kim, Seung-Mo Hong, on behalf of the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists
Cancer Res Treat. 2020;52(1):263-276.   Published online July 12, 2019
DOI: https://doi.org/10.4143/crt.2019.192
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The most recent 2017 World Health Organization (WHO) classification of pancreatic neuroendocrine neoplasms (PanNENs) has refined the three-tiered 2010 scheme by separating grade 3 pancreatic neuroendocrine tumors (G3 PanNETs) from poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs). However, differentiating between G3 Pan- NETs and PanNECs is difficult in clinical practice.
Materials and Methods
Eighty-two surgically resected PanNENs were collected from 16 institutions and reclassified according to the 2017 WHO classification based on the histological features and proliferation index (mitosis and Ki-67). Immunohistochemical stains for ATRX, DAXX, retinoblastoma, p53, Smad4, p16, and MUC1 were performed for 15 high-grade PanNENs.
Results
Re-classification resulted in 20 G1 PanNETs (24%), 47 G2 PanNETs (57%), eight G3 well-differentiated PanNETs (10%), and seven poorly differentiated PanNECs (9%). PanNECs showed more frequent diffuse nuclear atypia, solid growth patterns and apoptosis, less frequent organoid growth and regular vascular patterns, and absence of low-grade PanNET components than PanNETs. The Ki-67 index was significantly higher in PanNEC (58.2%± 15.1%) compared to G3 PanNET (22.6%±6.1%, p < 0.001). Abnormal expression of any two of p53, p16, MUC1, and Smad4 could discriminate PanNECs from G3 PanNETs with 100% specificity and 87.5% sensitivity.
Conclusion
Histological features supporting the diagnosis of PanNECs over G3 PanNETs were the absence of a low-grade PanNET component in the tumor, the presence of diffuse marked nuclear atypia, solid growth pattern, frequent apoptosis and markedly increased proliferative activity with homogeneous Ki-67 labeling. Immunohistochemical stains for p53, p16, MUC1, and Smad4 may be helpful in distinguishing PanNECs from G3 PanNETs in histologically ambiguous cases, especially in diagnostic practice when only small biopsied tissues are available.

Citations

Citations to this article as recorded by  
  • Malignant potential of neuroendocrine microtumor of the pancreas harboring high-grade transformation: lesson learned from a patient with von Hippel-Lindau syndrome
    Jongwon Lee, Kyung Jin Lee, Dae Wook Hwang, Seung-Mo Hong
    Journal of Pathology and Translational Medicine.2024; 58(2): 91.     CrossRef
  • Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation
    Atsuko Kasajima, Nicole Pfarr, Eva-Maria Mayr, Ayako Ura, Elisa Moser, Alexander von Werder, Abbas Agaimy, Marianne Pavel, Günter Klöppel
    Endocrine Pathology.2024;[Epub]     CrossRef
  • The Complex Histopathological and Immunohistochemical Spectrum of Neuroendocrine Tumors—An Overview of the Latest Classifications
    Ancuța-Augustina Gheorghișan-Gălățeanu, Andreea Ilieșiu, Ioana Maria Lambrescu, Dana Antonia Țăpoi
    International Journal of Molecular Sciences.2023; 24(2): 1418.     CrossRef
  • All Together Now
    Pari Jafari, Aliya N. Husain, Namrata Setia
    Surgical Pathology Clinics.2023; 16(1): 131.     CrossRef
  • A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors
    Mauro D. Donadio, Ângelo B. Brito, Rachel P. Riechelmann
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus
    Tomoyuki Okumura, Tsutomu Fujii, Kenji Terabayashi, Takashi Kojima, Shigeru Takeda, Tomomi Kashiwada, Kazuhiro Toriyama, Susumu Hijioka, Tatsuya Miyazaki, Miho Yamamoto, Shunsuke Tanabe, Yasuhiro Shirakawa, Masayuki Furukawa, Yoshitaka Honma, Isamu Hoshin
    Oncology Letters.2023;[Epub]     CrossRef
  • The association between jaundice and poorly differentiated pancreatic neuroendocrine neoplasms (Ki67 index > 55.0%)
    Yongkang Liu, Jiangchuan Wang, Hao Zhou, Zicheng Wei, Jianhua Wang, Zhongqiu Wang, Xiao Chen
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features
    Atsuko Kasajima, Björn Konukiewitz, Anna Melissa Schlitter, Wilko Weichert, Günter Klöppel
    Virchows Archiv.2022; 480(2): 359.     CrossRef
  • An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms
    Tiago Bordeira Gaspar, José Manuel Lopes, Paula Soares, João Vinagre
    Endocrine-Related Cancer.2022; 29(12): R191.     CrossRef
  • Solid pancreatic masses in children: A review of current evidence and clinical challenges
    Kelli N. Patterson, Andrew T. Trout, Archana Shenoy, Maisam Abu-El-Haija, Jaimie D. Nathan
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review
    Tiziana Feola, Roberta Centello, Franz Sesti, Giulia Puliani, Monica Verrico, Valentina Di Vito, Cira Di Gioia, Oreste Bagni, Andrea Lenzi, Andrea M. Isidori, Elisa Giannetta, Antongiulio Faggiano
    Cancers.2021; 13(6): 1247.     CrossRef
  • Risk of cancer in patients with recurrent aphthous stomatitis in Korea
    Ki Jin Kwon, Su Jin Jeong, Young-Gyu Eun, In Hwan Oh, Young Chan Lee
    Medicine.2021; 100(16): e25628.     CrossRef
  • Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions
    Anna Pellat, Anne Ségolène Cottereau, Lola-Jade Palmieri, Philippe Soyer, Ugo Marchese, Catherine Brezault, Romain Coriat
    Cancers.2021; 13(10): 2448.     CrossRef
  • Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
    Anna Pellat, Anne Ségolène Cottereau, Benoit Terris, Romain Coriat
    Cancers.2021; 13(15): 3766.     CrossRef
  • Pancreatic Masses in Children and Young Adults: Multimodality Review with Pathologic Correlation
    Lisa Qiu, Andrew T. Trout, Rama S. Ayyala, Sara Szabo, Jaimie D. Nathan, James I. Geller, Jonathan R. Dillman
    RadioGraphics.2021; 41(6): 1766.     CrossRef
  • CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms


    Xin Chen, Chuangen Guo, Wenjing Cui, Ke Sun, Zhongqiu Wang, Xiao Chen
    Cancer Management and Research.2020; Volume 12: 4625.     CrossRef
  • Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
    Lingaku Lee, Tetsuhide Ito, Robert T Jensen
    Expert Review of Anticancer Therapy.2019; 19(12): 1029.     CrossRef
  • 10,155 View
  • 320 Download
  • 15 Web of Science
  • 17 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP